|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023981,
umls-concept:C0030705,
umls-concept:C0031809,
umls-concept:C0034656,
umls-concept:C0039789,
umls-concept:C0087111,
umls-concept:C0288672,
umls-concept:C0524527,
umls-concept:C0681867,
umls-concept:C0948089,
umls-concept:C1556095
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2009-10-7
|
|
pubmed:abstractText |
Abciximab has been found to reduce major adverse cardiovascular events in patients with acute coronary syndrome (ACS). A previous study reported on the tolerability of biogeneric abciximab in patients with ACS. This formulation has been approved by the Korea Food and Drug Administration and is currently being marketed. Its ex vivo antiplatelet effect, however, has not been compared with that of branded abciximab.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1879-114X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
31
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1804-11
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19808139-Acute Coronary Syndrome,
pubmed-meshheading:19808139-Aged,
pubmed-meshheading:19808139-Angioplasty, Balloon, Coronary,
pubmed-meshheading:19808139-Antibodies, Monoclonal,
pubmed-meshheading:19808139-Anticoagulants,
pubmed-meshheading:19808139-Asian Continental Ancestry Group,
pubmed-meshheading:19808139-Drugs, Generic,
pubmed-meshheading:19808139-Female,
pubmed-meshheading:19808139-Hemorrhage,
pubmed-meshheading:19808139-Heparin,
pubmed-meshheading:19808139-Humans,
pubmed-meshheading:19808139-Immunoglobulin Fab Fragments,
pubmed-meshheading:19808139-Infusions, Intravenous,
pubmed-meshheading:19808139-Korea,
pubmed-meshheading:19808139-Male,
pubmed-meshheading:19808139-Middle Aged,
pubmed-meshheading:19808139-Platelet Function Tests,
pubmed-meshheading:19808139-Prospective Studies,
pubmed-meshheading:19808139-Retroperitoneal Space,
pubmed-meshheading:19808139-Therapeutic Equivalency
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: a prospective, open-label, randomized, controlled study in Korean patients.
|
|
pubmed:affiliation |
Department of Internal Medicine, Cardiovascular Center, Seoul National University Hospital, Seoul 110-744, Korea.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
